Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Leases (2019 - 2025)

Agios Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $40.2 million for Q4 2025.

  • For Q4 2025, Operating Leases changed 0.0% year-over-year to $40.2 million; the TTM value through Dec 2025 reached $40.2 million, changed 0.0%, while the annual FY2025 figure was $40.2 million, 0.0% changed from the prior year.
  • Operating Leases reached $40.2 million in Q4 2025 per AGIO's latest filing, up from $26.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $100.9 million in Q2 2021 to a low of $26.5 million in Q3 2025.
  • Average Operating Leases over 5 years is $68.6 million, with a median of $73.7 million recorded in 2022.
  • Peak YoY movement for Operating Leases: increased 0.0% in 2022, then crashed 56.39% in 2025.
  • A 5-year view of Operating Leases shows it stood at $85.7 million in 2021, then decreased by 15.95% to $72.0 million in 2022, then decreased by 20.85% to $57.0 million in 2023, then fell by 29.45% to $40.2 million in 2024, then changed by 0.0% to $40.2 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Operating Leases are $40.2 million (Q4 2025), $26.5 million (Q3 2025), and $31.2 million (Q2 2025).